Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact New to PCSK9 Forum News from the 14th Expert Meeting of the Editorial Board of PCSK9 Education and Research Forum Real-world practice has to adapt to attain guideline-recommended LDL cholesterol goals post-myocardial infarction. The final presentations from this Expert Meeting focus on the role of PCSK9 inhibition in this clinical setting. PCSK9 inhibition: The evolving treatment paradigm post-myocardial infarction A perspective from Prof Gregory Schwartz (University of Colorado School of Medicine, Aurora, Colorado, USA) Prof Schwartz discusses the relevance of timing of upfront combination therapy, and eligibility for the addition of a PCSK9 inhibitor, using evidence from the ODYSSEY OUTCOMES study. Watch the presentation » PCSK9 inhibition: The evolving treatment paradigm post-myocardial infarction A perspective from Prof Robert Giugliano (Brigham and Women's Hospital, Harvard Medical School, Boston, USA) Prof Giugliano discusses evidence from FOURIER to support the use of combination therapy with a PCSK9 inhibitor to attain LDL cholesterol in patients with familial hypercholesterolaemia and established cardiovascular disease. Watch the presentation » Like us For the latest updates, PCSK9 news and analysis. Follow us Hot topics, news and conference reports. YouTube Channel For videos, interviews and webcasts from leading experts. Educational Partners and Supporters Copyright PCSK9 Forum 2021. Please click here to unsubscribe from future mailings . View on the web